{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:10:20Z","timestamp":1758741020359,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006677","name":"Washington State Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA050985"],"award-info":[{"award-number":["R25DA050985"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013382","name":"Institute of Translational Health Sciences","doi-asserted-by":"crossref","award":["UL1TR002319"],"award-info":[{"award-number":["UL1TR002319"]}],"id":[{"id":"10.13039\/100013382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatitis C infection (HCV) and opioid use disorder (OUD) are syndemic in the U.S., thus primary care providers (PCPs) who treat OUD by prescribing buprenorphine can play key roles to advance HCV elimination targets. We compared HCV screening and treatment among PCPs who do and do not prescribe buprenorphine in Washington (WA) State.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study utilized a cross-sectional survey of PCPs in WA State, designed to characterize HCV care delivery practices and experiences\/attitudes toward HCV. In this study, the independent variable was self-reported buprenorphine prescribing, and the main outcomes were (1) guideline-concordant HCV screening and (2) directly providing treatment for HCV. We used descriptive statistics to describe respondent characteristics. We used logistic regression to assess the association between buprenorphine prescribing status and HCV screening and treatment outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our sample included 73 PCPs, of whom 55% prescribe buprenorphine. We found that 25% of buprenorphine prescribers directly treated HCV. There was over a 2x greater relative odds that buprenorphine prescribers would correctly screen for HCV relative to non-prescribers (OR\u2009=\u20092.24; 95% CI: 0.67\u20138.18, <jats:italic>p<\/jats:italic>\u2009=\u2009.20) and a nearly 2.5x greater relative odds that they would treat HCV relative to non-prescribers (OR\u2009=\u20092.42; 0.72\u20139.61; <jats:italic>p<\/jats:italic>\u2009=\u2009.17), although both findings were not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In a sample of PCPs in WA state, buprenorphine prescribers compared to non-prescribers appear more likely to screen for and directly treat HCV, yet only a minority treat HCV. Interventions are needed to enhance HCV guideline-concordant care among these and all PCPs on the frontlines of caring for persons with OUD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00603-9","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:41:08Z","timestamp":1758739268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis C care delivery practices among buprenorphine prescribers and non-prescribers: results from a survey of Washington state primary care providers"],"prefix":"10.1186","volume":"20","author":[{"given":"Jocelyn R.","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia M.","family":"Mohabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire B.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emalie","family":"Huriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Stockton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Rouvere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"10","key":"603_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","volume":"15","author":"KN Ly","year":"2016","unstructured":"Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the united states, 2003\u20132013. Clin Infect Dis May. 2016;15(10):1287\u20138. https:\/\/doi.org\/10.1093\/cid\/ciw111","journal-title":"Clin Infect Dis May"},{"key":"603_CR2","unstructured":"Centers for Disease Control and Prevention, Hepatitis C. surveillance 2021. Updated August 7. Accessed 12 September, 2024. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c.htm\/"},{"issue":"18","key":"603_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.15585\/mmwr.mm6618a2","volume":"12","author":"CA Campbell","year":"2017","unstructured":"Campbell CA, Canary L, Smith N, Teshale E, Ryerson AB, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs\u2014United states, 2015\u20132016. MMWR Morb Mortal Wkly Rep May. 2017;12(18):465\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm6618a2","journal-title":"MMWR Morb Mortal Wkly Rep May"},{"key":"603_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.drugalcdep.2018.03.049","volume":"1","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Pollini RA. Injection drug use, HIV\/HCV, and related services in nonurban areas of the united states: A systematic review. Drug Alcohol Depend Jul. 2018;1:188:239\u201350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.03.049","journal-title":"Drug Alcohol Depend Jul"},{"issue":"10","key":"603_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jama.2020.1123","volume":"10","author":"DK Owens","year":"2020","unstructured":"Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA Mar. 2020;10(10):970\u20135. https:\/\/doi.org\/10.1001\/jama.2020.1123","journal-title":"JAMA Mar"},{"issue":"2","key":"603_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","volume":"10","author":"S Schillie","year":"2020","unstructured":"Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among Adults - United states, 2020. MMWR Recomm Rep Apr. 2020;10(2):1\u201317. https:\/\/doi.org\/10.15585\/mmwr.rr6902a1","journal-title":"MMWR Recomm Rep Apr"},{"issue":"12","key":"603_CR7","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1111\/liv.14152","volume":"39","author":"NH Latham","year":"2019","unstructured":"Latham NH, Doyle JS, Palmer AY, et al. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int Dec. 2019;39(12):2244\u201360. https:\/\/doi.org\/10.1111\/liv.14152","journal-title":"Liver Int Dec"},{"key":"603_CR8","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. Accessed 12. September, 2024. https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06\/"},{"key":"603_CR9","unstructured":"Washington State Health Care Authority. Eliminating hepatitis C in Washington State. Updated July 26. Accessed 10. December, 2024. https:\/\/www.hca.wa.gov\/assets\/program\/HCA-HCV-elimination-breif.pdf"},{"issue":"19","key":"603_CR10","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2018.15782","volume":"20","author":"MR Trusheim","year":"2018","unstructured":"Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis C treatment\u2014the Netflix model. JAMA Nov. 2018;20(19):1977\u20138. https:\/\/doi.org\/10.1001\/jama.2018.15782","journal-title":"JAMA Nov"},{"issue":"8","key":"603_CR11","doi-asserted-by":"publisher","first-page":"e212291","DOI":"10.1001\/jamahealthforum.2021.2291","volume":"2","author":"SG Auty","year":"2021","unstructured":"Auty SG, Shafer PR, Griffith KN. Medicaid subscription-based payment models and implications for access to hepatitis C medications. JAMA Health Forum Aug. 2021;2(8):e212291. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.2291","journal-title":"JAMA Health Forum Aug"},{"issue":"21","key":"603_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7321a4","volume":"30","author":"CA Tsang","year":"2024","unstructured":"Tsang CA, Tonzel J, Symum H, et al. State-specific hepatitis C virus clearance cascades - United states, 2013\u20132022. MMWR Morb Mortal Wkly Rep May. 2024;30(21):495\u2013500. https:\/\/doi.org\/10.15585\/mmwr.mm7321a4","journal-title":"MMWR Morb Mortal Wkly Rep May"},{"key":"603_CR13","unstructured":"American Association for the Study of Liver Disease. Key populations: Identification and management of HCV in people who inject drugs. Updated December 19. Accessed 12 September, 2024. https:\/\/www.hcvguidelines.org\/unique-populations\/pwid\/"},{"key":"603_CR14","unstructured":"World Health Organization. Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics. 2022."},{"key":"603_CR15","doi-asserted-by":"publisher","unstructured":"Perlman DC, Jordan AE. Apr. The syndemic of opioid misuse, overdose, HCV, and HIV: Structural-level causes and interventions. Curr HIV\/AIDS Rep. 2018;15(2):96\u2013112. https:\/\/doi.org\/10.1007\/s11904-018-0390-3","DOI":"10.1007\/s11904-018-0390-3"},{"issue":"6","key":"603_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"39","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff (Millwood) Jun. 2020;39(6):984\u201392. https:\/\/doi.org\/10.1377\/hlthaff.2019.01622","journal-title":"Health Aff (Millwood) Jun"},{"key":"603_CR17","unstructured":"R: a language and environment for statistical computing. Version 4.3.2. R Foundation for Statistical Computing; 2023. https:\/\/www.R-project.org\/"},{"key":"603_CR18","unstructured":"Washington State Department of Health. Hepatitis C data snapshot: Washington State 2021. Updated March. Accessed 11. December, 2024. https:\/\/doh.wa.gov\/sites\/default\/files\/2023-03\/150-203-HepatitisC-DataSnapshotWashingtonState2021.pdf"},{"issue":"6","key":"603_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/cid\/ciae025","volume":"14","author":"CD Varley","year":"2024","unstructured":"Varley CD, Lowy E, Cartwright EJ, et al. Success of the US veterans health administration\u2019s hepatitis C virus care continuum in the Direct-acting antiviral era. Clin Infect Dis Jun. 2024;14(6):1571\u20139. https:\/\/doi.org\/10.1093\/cid\/ciae025","journal-title":"Clin Infect Dis Jun"},{"key":"603_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","volume":"169","author":"JI Tsui","year":"2016","unstructured":"Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend Dec 1. 2016;169:101\u20139. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.10.021","journal-title":"Drug Alcohol Depend Dec 1"},{"key":"603_CR21","unstructured":"American Association for the Study of Liver Disease. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Accessed 12. September, 2024. https:\/\/www.hcvguidelines.org\/"},{"key":"603_CR22","doi-asserted-by":"publisher","first-page":"215013192513595","DOI":"10.1177\/21501319251359547","volume":"16","author":"JR James","year":"2025","unstructured":"James JR, Huriaux E, Stockton J, Cole A, Tsui JI. Use of pharmacists and collaborative practice agreements to treat hepatitis C: A survey of primary care clinicians in Washington state. J Prim Care Community Health. 2025;16:21501319251359547. https:\/\/doi.org\/10.1177\/21501319251359547","journal-title":"J Prim Care Community Health"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00603-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:41:11Z","timestamp":1758739271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00603-9","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}